With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...

Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a ...

Messenger RNA carries genetic information from DNA in the highly protected nucleus out to the rest of the cell, where structures called ribosomes can build proteins according to the DNA blueprint.

America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

The American pharmaceutical company Moderna announced that the United States Food and Drug Administration (FDA) has refused ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...